Brief: Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study Of Once-Daily Alixorexton IN PATIENTS WITH NARCOLEPSY TYPE 1
21/07/2025 11:10
July 21 (Reuters) - Alkermes Plc ALKS.O: ALKERMES ANNOUNCES POSITIVE TOPLINE RESULTS FROM VIBRANCE-1 PHASE 2 STUDY OF ONCE-DAILY ALIXOREXTON IN PATIENTS WITH NARCOLEPSY TYPE 1 ALKERMES PLC - ALIXOREXTON SHOWS SIGNIFICANT IMPROVEMENTS IN WAKEFULNESS IN NT1 ALKERMES PLC - ALIXOREXTON GENERALLY WELL TOLERATED AT ALL DOSES ALKERMES PLC - ALIXOREXTON ADVANCING TO PHASE 3 DEVELOPMENT IN NARCOLEPSY Source text: ID:nPreZlkGqa Further company coverage: ALKS.O ((Reuters.Briefs@thomsonreuters.com;))